Association of gout with CAD and effect of antigout therapy on CVD risk among gout patients. (24th February 2020)

• Record Type: Journal Article
• Authors: Huang, Wei-Shih; Lin, Cheng-Li; Tsai, Chon-Haw; Chang, Kuang-Hsi
• Is Part Of: Journal of investigative medicine. Volume 68:Number 5(2020)
• Page Start: 972
• Page End: 979
• Publication Date: 2020-02-24
• Subjects: cardiovascular diseases -- coronary disease; Clinical medicine -- Periodicals; Medicine -- Research -- Periodicals; Medicine; Research -- United States; Clinical medicine; Medicine -- Research; Periodicals; 616.075
• DOI: 10.1136/jim-2019-001140
• Languages: English
• ISSNs: 1081-5589

Abstract

Abstract : Hyperuricemia has been identified as an independent risk factor for coronary artery disease (CAD), with a dose–response association. In this study, we explored the causal association between gout and antigout medication and the risk of incidental CAD. We sampled data from the National Health Insurance Research Database and recruited 37, 091 patients as the gout cohort, and 37, 091 controls. Our primary endpoint was the diagnosis of CAD during follow-up. The overall study population was followed up until CAD diagnosis, withdrawal from the National Health Insurance program, or the end of the study. Cox proportional hazards regression models were used to examine the effect of gout on the risk of CAD, represented by the HR with the 95% CI. Patients with gout were at greater risk of CAD, compared with those without gout: HR=1.49 after adjusting for potential confounders. Non-steroidal anti-inflammatory drugs and prednisolone use was associated with a reduced risk of CAD: HR=0.63 and 0.50, respectively. Patients with gout, treated with antigout medication, exhibited a reduced risk of CAD compared with non-gout patients. Among patients with gout, those on antigout therapy had 32% lower risk compared with those not on antigout therapy: adjusted HR=0.68, 95% CI 0.63 to 0.73. Gout increases the risk of CAD, and the use of antigout medication reduces CAD risk. These results indicate that gout or hyperuricemia is a modifiable risk factor for CAD.